| Document |
Document Title |
|
WO/2022/270482A1 |
The present invention provides: sugar chain immobilized polymer particles in which a hydrophobized sugar chain polypeptide is firmly immobilized to the outermost surface of the polymer particles and the sugar chain density on the surface...
|
|
WO/2022/259719A1 |
The present invention addresses the problem of providing a means of detecting infection with Treponema pallidum bacterium at a higher sensitivity. The present inventor found that, in the measurement of anti-T. pallidum antibody in a body...
|
|
WO/2022/243636A1 |
The present invention relates to a microfluidic chip capable of attracting and trapping a specific biological element, the chip comprising: - a reservoir (1) formed of a matrix comprising a chemoattractant compound capable of attracting ...
|
|
WO/2022/239704A1 |
The present invention addresses the problem of providing a method for eliminating a glycosylation isomer from an antibody drug, etc. The present invention provides, for example, a purification method of an antibody composition, said puri...
|
|
WO/2022/239810A1 |
Provided is a method for producing a dry microcarrier for cell cultivation, the method comprising: a step of immersing, using a solvent including gelatin, an alginic acid fine particulate gel including a cation having a valency of two or...
|
|
WO/2022/232924A1 |
The present invention is based on the surprising finding that Wnt7a, and other Wnt family members, are trafficked to extracellular vesicles (EVs) via interactions with coatomer proteins. Extracellular vesicle signal peptides (ESPs), each...
|
|
WO/2022/232321A1 |
Provided are chimeric antibodies containing an ultralong CDR3, such as based on a bovine antibody sequence or a humanized sequence thereof, in which a portion of the CDR3 of the heavy chain is replaced by a heterologous sequence, for ins...
|
|
WO/2022/227122A1 |
Disclosed is a method for preparing biodiesel by using dual MOFs immobilized lipase, which comprises the following steps: preparing ZIF-8; preparing ANL/ZIF-8 by using ZIF-8; preparing a three-dimensional ordered polystyrene template; pr...
|
|
WO/2022/217359A1 |
Described herein is a functionalized biological membrane comprising an endogenous bilayer and one or more modifying protein molecules embedded therein or attached thereto. Also described herein is a method of preparing a functionalized b...
|
|
WO/2022/215341A1 |
This method for creating a calibration curve comprises: a step in which a plurality of standard solutions that include an amyloid β-related peptide and a surfactant and in which the concentration of the amyloid β-related peptide differ...
|
|
WO/2022/202312A1 |
Disclosed are insoluble particles containing a granular carrier and a protein or a peptide carried on the granular carrier, wherein the α-amino group of at least one N-terminal amino acid residue of the protein or peptide is protected s...
|
|
WO/2022/196179A1 |
A biosensor 1 is a biosensor of a field effect transistor type, which is equipped with an insulating substrate 10 and a measurement sensor S1 and a reference sensor S2 both provided on the insulating substrate 10. On the measurement sens...
|
|
WO/2022/184899A1 |
The present invention is concerned with materials and methods for mediating eukaryotic cell attachment to rigid surfaces. In particular, the invention is concerned with coatings for forming cell attachment surfaces, preferably for cell c...
|
|
WO/2022/187586A1 |
The present disclosure provides antibodies, and fragments thereof, conjugated to an oligonucleotide, wherein the oligonucleotide is not hybridized to a DNA dendrimer, compositions comprising the same, and uses thereof in methods of detec...
|
|
WO/2022/177003A1 |
The present invention provides a monoclonal antibody capable of binding to tetranor-PGDM specifically or a fragment of the monoclonal antibody.
|
|
WO/2022/166720A1 |
Provided is a fusion protein, comprising a protein having a hydrophobic region, a peptide linker, a protein fusion receptor. The peptide linker links the protein having a hydrophobic region to the protein fusion receptor. The protein fus...
|
|
WO/2022/163041A1 |
Provided are: an indole-structure-selective reaction agent and an indole-structure-selective crosslinking agent which are capable of selectively modifying, under mild conditions, an indole structure of a molecule (e.g., tryptophan) conta...
|
|
WO/2022/155704A1 |
Disclosed are polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. More particularly, the invention provides peptide mimetics of PD-L1...
|
|
WO/2022/158497A1 |
In this invention, a hybridoma is prepared using, as the antigen, a protein with its secretion signal added to the receptor-binding domain (RBD, positions 319-589) of SARS-CoV-2 spike protein and G196 tag sequence (DLVPR) with His6 seque...
|
|
WO/2022/153898A1 |
Disclosed are insoluble particles comprising a particulate carrier and an antibody to a target antigen, said antibody being carried on the particulate carrier, wherein the C-terminal amino acid in a heavy chain of the antibody is lysine.
|
|
WO/2022/138718A1 |
The purpose of the present invention is to provide a polypeptide, which has excellent alkali stability and allows the elution of immunoglobulin or a fragment of the same, which has been bound thereto, in a weakly acidic region, by modify...
|
|
WO/2022/138758A1 |
Insoluble particles containing a granular carrier and an antibody to a target antigen carried on the granular carrier, no sugar chain being bonded to the heavy chain of the antibody.
|
|
WO/2022/138984A1 |
The present invention provides a neurite outgrowth promoter for promoting neurite growth on nerve cells of a postnatal mammalian individual for use in a condition in which an effective amount of a glial cell-derived neurotrophic factor (...
|
|
WO/2022/127326A1 |
Disclosed in the present invention are a protein and multi-stage porous metal-organic framework complex, a preparation method therefor, and an application thereof, relating to the technical field of biological material preparation. In th...
|
|
WO/2022/123054A1 |
The present invention relates to a method of making a composite material. The method comprises: a) providing a dehydrated protein-polymer surfactant conjugate (PPSC); b) heating the dehydrated PPSC above its annealing temperature, to a P...
|
|
WO/2022/115791A1 |
This invention relates to the compositions and methods for labeling antibodies and other proteins and targeting agents with a helical bundle protein that is functionalized with cargo. Cargos can include but are not limited to fluorescent...
|
|
WO/2022/103793A1 |
The present disclosure relates to proteins comprising a SARS-CoV-2 nucleoprotein- binding domain for detection of SARS-CoV-2, methods, compositions and kits thereof.
|
|
WO/2022/097500A1 |
A protein or peptide crosslinking agent which is represented by formula (I). [In the formula, A is a hydrogen atom, a C1-6 alkyl group which may be substituted with a phenyl group or a halogen atom, or a phenyl group.]
|
|
WO/2022/087804A1 |
Provided are a puromycin linker and an application thereof in synthesis of an in-vitro nucleic acid displayed peptide. The puromycin linker is a modified and unbranched single-stranded DNA; the single-stranded DNA comprises a first stret...
|
|
WO/2022/080486A1 |
The present invention addresses the problem of providing a polypeptide with further reduced binding properties with respect to D-biotin, and which strongly binds to L-biotin. Provided is a polypeptide belonging to the avidin-streptavidin...
|
|
WO/2022/073404A1 |
Provided is a fusion protein for a biosensing element; the fusion protein comprises glucose oxidase (GOD) and a carbohydrate-binding module (CBM); and the GOD is linked to the CBM by means of a linker peptide. The biosensing element spec...
|
|
WO/2022/074402A1 |
There is described a nanoparticle comprising one or more peptides having a sequence comprising the motif GLLxLLxLLLxAAG, wherein each x is independently selected from arginine (R), histidine (H), lysine (K), aspartic acid (D) or glutamic...
|
|
WO/2022/074380A1 |
The present invention relates to new synthetically generated carboxysome shells, shells encapsulating selected catalytically active enzymes, cells including the shells and methods of making the shells and methods of encapsulation. The in...
|
|
WO/2022/071849A1 |
The present application relates to a matrix for selective binding of at least one component from a body fluid, the matrix having a porous structure; wherein a peptide is covalently attached to the matrix via a linker; and wherein the mat...
|
|
WO/2022/067446A1 |
Disclosed is a proteolipid vesicle (PLV) for delivering a therapeutic cargo, such as nucleic acids, polypeptides and molecules, to a cell, the proteolipid vesicle having a lipid nanoparticle comprising one or more ionizable lipids and on...
|
|
WO/2022/069768A1 |
The invention relates to a new combinations of boron compounds and adjuvants and compositions thereof, suitable for use in a method to induce myotube formation and suppress cell mortality in a mammal in need thereof and for the treatment...
|
|
WO/2022/063892A1 |
The present invention provides a compound for the sequestration of undesirable neutralizing antibodies against viral vectors (as used in vaccines and in gene therapy) in a patient. The compound comprises an inert biopolymer scaffold and ...
|
|
WO/2022/063879A1 |
The present invention provides a compound for the sequestration of undesirable antibodies (e.g. related to an autoimmune disease) in a patient. The compound comprises an inert biopolymer scaffold, which is an anti-CD163 antibody or GD163...
|
|
WO/2022/063887A1 |
The present invention provides a compound for the sequestration of undesirable antibodies associated with hemophilia A, in particular when treated by factor VIII replacement therapy. The compound comprises a biopolymer scaffold and at le...
|
|
WO/2022/063882A1 |
The present invention provides a compound for the sequestration of undesirable antibodies associated with an autoantibody-mediated condition, such as Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), postural orthostatic tachy...
|
|
WO/2022/065052A1 |
Provided is a capture antibody which is immobilized on a solid-phase carrier and used for capturing a detection target substance, wherein at least a portion of a functional group of a first antibody having a specific binding activity to ...
|
|
WO/2022/063880A1 |
The present invention provides a compound for the sequestration of anti human muscle nicotinic acetylcholine receptor (AChR) autoantibodies, which are involved in the pathogenesis of MG. The compound comprises an inert biopolymer scaffol...
|
|
WO/2022/055993A1 |
Methods of treating irritable bowel syndrome (IBS) include the administration of an effective amount of an anti-microbial decapeptide NH2-Lys-Lys-Val-Val-Phe-Trp-Val-Lys-Phe-Lys-CO NH2 (SEQ ID NO 1) (KSL-W).
|
|
WO/2022/053844A1 |
The present invention provides a nanostructure (5) for lysis of a pathogenic bacteria in mammals. Said nanostructure (5) comprises one or more antimicrobial components (3) loaded into one or more carrier components (4) forming a core por...
|
|
WO/2022/051457A1 |
The present disclosure provides non-naturally occurring beta barrel proteins as defined, self-complementing multipartite beta barrel proteins, uses of such proteins, and methods for designing such proteins.
|
|
WO/2022/049600A1 |
The present disclosure discloses a method for assessing T cell-specific immune response against SARS-CoV-2, comprising contacting one or more samples with a peptide pool to obtain a mixture, wherein the peptide pool comprises three to fi...
|
|
WO/2022/031376A1 |
The invention encompasses emulsomes coated with S-layer fusion proteins, pharmaceutical compositions and vaccines comprising the emulsomes, and methods of use thereof for immunizing a patient.
|
|
WO/2022/023461A1 |
A specific epitope has been identified in the present invention, which is herein used for detecting and/or quantifying autoantibodies against alpha-fetoprotein (AFP) in a biological sample, and consequently for the in vitro diagnosis of ...
|
|
WO/2022/016751A1 |
Provided are a molecular diagnosis and treatment formulation, a preparation method therefor and use thereof. The formulation comprises: (1) an effect component, i.e. a diagnostic compound and/or a drug for treating endometriosis; and (2)...
|
|
WO/2022/011466A1 |
There is provided a surface functionalized with cross linking groups adapted to receive antibodies and/or fragments thereof. The surface has an antibody binding biomolecule having a linker region which is covalently crosslinked to functi...
|
